510(k)s Are Subject To Good Laboratory Practice Regs – FDA Draft Guidance
Executive Summary
Device manufacturers must declare compliance or explain noncompliance to good laboratory practice regulations for nonclinical studies in all premarket submission types, according to new draft guidance. This has not been the requirement for 510(k)s up until now, says the former CDRH 510(k) policy chief.
You may also be interested in...
510(k) Guidance Footnote May Signal Greater FDA Oversight Of Preclinical Testing
Device industry experts say a seemingly minor footnote to the recent 510(k) program draft guidance could create a new requirement for nonclinical studies.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.